Xeris Pharmaceuticals, Inc.


Date of Award

05.27.2015

Program

Type 1 Diabetes, Improve Outcomes

Amount

$1,004,475

Term of Grant

15 months

Project Title

Sub-chronic Preclinical Toxicity Study to Further Development of a Stable Liquid Glucagon

Project Description

Funding to conduct the initial preclinical study to demonstrate the safety of XeriSol glucagon sub-chronically, to enable future longer-term clinical studies that would allow chronic repeat dosing of XeriSol glucagon in people with type 1 diabetes.